scholarly journals Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review

10.2196/14630 ◽  
2019 ◽  
Vol 21 (8) ◽  
pp. e14630 ◽  
Author(s):  
Andrew Lukas Yin ◽  
David Hachuel ◽  
John P Pollak ◽  
Ellen J Scherl ◽  
Deborah Estrin
Keyword(s):  
Inflammatory Bowel Disease ◽  
Mobile Health ◽  
Bowel Disease ◽  
Digital Health ◽  
Clinical Care ◽  
Mobile App ◽  
Health Apps ◽  
Patient Reported ◽  
Inflammatory Bowel

Background Digital health is poised to transform health care and redefine personalized health. As Internet and mobile phone usage increases, as technology develops new ways to collect data, and as clinical guidelines change, all areas of medicine face new challenges and opportunities. Inflammatory bowel disease (IBD) is one of many chronic diseases that may benefit from these advances in digital health. This review intends to lay a foundation for clinicians and technologists to understand future directions and opportunities together. Objective This review covers mobile health apps that have been used in IBD, how they have fit into a clinical care framework, and the challenges that clinicians and technologists face in approaching future opportunities. Methods We searched PubMed, Scopus, and ClinicalTrials.gov to identify mobile apps that have been studied and were published in the literature from January 1, 2010, to April 19, 2019. The search terms were (“mobile health” OR “eHealth” OR “digital health” OR “smart phone” OR “mobile app” OR “mobile applications” OR “mHealth” OR “smartphones”) AND (“IBD” OR “Inflammatory bowel disease” OR “Crohn's Disease” (CD) OR “Ulcerative Colitis” (UC) OR “UC” OR “CD”), followed by further analysis of citations from the results. We searched the Apple iTunes app store to identify a limited selection of commercial apps to include for discussion. Results A total of 68 articles met the inclusion criteria. A total of 11 digital health apps were identified in the literature and 4 commercial apps were selected to be described in this review. While most apps have some educational component, the majority of apps focus on eliciting patient-reported outcomes related to disease activity, and a few are for treatment management. Significant benefits have been seen in trials relating to education, quality of life, quality of care, treatment adherence, and medication management. No studies have reported a negative impact on any of the above. There are mixed results in terms of effects on office visits and follow-up. Conclusions While studies have shown that digital health can fit into, complement, and improve the standard clinical care of patients with IBD, there is a need for further validation and improvement, from both a clinical and patient perspective. Exploring new research methods, like microrandomized trials, may allow for more implementation of technology and rapid advancement of knowledge. New technologies that can objectively and seamlessly capture remote data, as well as complement the clinical shift from symptom-based to inflammation-based care, will help the clinical and health technology communities to understand the full potential of digital health in the care of IBD and other chronic illnesses.

scholarly journals Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review (Preprint)

2019 ◽  
Author(s):  
Andrew Lukas Yin ◽  
David Hachuel ◽  
John P Pollak ◽  
Ellen J Scherl ◽  
Deborah Estrin
Keyword(s):  
Inflammatory Bowel Disease ◽  
Mobile Health ◽  
Bowel Disease ◽  
Digital Health ◽  
Clinical Care ◽  
Mobile App ◽  
Health Apps ◽  
Patient Reported ◽  
Inflammatory Bowel

BACKGROUND Digital health is poised to transform health care and redefine personalized health. As Internet and mobile phone usage increases, as technology develops new ways to collect data, and as clinical guidelines change, all areas of medicine face new challenges and opportunities. Inflammatory bowel disease (IBD) is one of many chronic diseases that may benefit from these advances in digital health. This review intends to lay a foundation for clinicians and technologists to understand future directions and opportunities together. OBJECTIVE This review covers mobile health apps that have been used in IBD, how they have fit into a clinical care framework, and the challenges that clinicians and technologists face in approaching future opportunities. METHODS We searched PubMed, Scopus, and ClinicalTrials.gov to identify mobile apps that have been studied and were published in the literature from January 1, 2010, to April 19, 2019. The search terms were (“mobile health” OR “eHealth” OR “digital health” OR “smart phone” OR “mobile app” OR “mobile applications” OR “mHealth” OR “smartphones”) AND (“IBD” OR “Inflammatory bowel disease” OR “Crohn's Disease” (CD) OR “Ulcerative Colitis” (UC) OR “UC” OR “CD”), followed by further analysis of citations from the results. We searched the Apple iTunes app store to identify a limited selection of commercial apps to include for discussion. RESULTS A total of 68 articles met the inclusion criteria. A total of 11 digital health apps were identified in the literature and 4 commercial apps were selected to be described in this review. While most apps have some educational component, the majority of apps focus on eliciting patient-reported outcomes related to disease activity, and a few are for treatment management. Significant benefits have been seen in trials relating to education, quality of life, quality of care, treatment adherence, and medication management. No studies have reported a negative impact on any of the above. There are mixed results in terms of effects on office visits and follow-up. CONCLUSIONS While studies have shown that digital health can fit into, complement, and improve the standard clinical care of patients with IBD, there is a need for further validation and improvement, from both a clinical and patient perspective. Exploring new research methods, like microrandomized trials, may allow for more implementation of technology and rapid advancement of knowledge. New technologies that can objectively and seamlessly capture remote data, as well as complement the clinical shift from symptom-based to inflammation-based care, will help the clinical and health technology communities to understand the full potential of digital health in the care of IBD and other chronic illnesses.

scholarly journals Is Digital Health Intervention Effective in Inflammatory Bowel Disease Patients?

2021 ◽  
pp. 1-2
Author(s):  
Bilge Roj Gunerhanal ◽  
Merve Guney-Coskun
Keyword(s):  
Inflammatory Bowel Disease ◽  
Quality Of Care ◽  
Health Monitoring ◽  
Bowel Disease ◽  
Digital Health ◽  
Management Strategies ◽  
Care Quality ◽  
Technological Advances ◽  
Inflammatory Bowel

Technological advances now permit self-management strategies using mobile applications which could greatly benefit patient care. The purpose of this study was to investigate whether the use of the inflammatory bowel disease (IBD) digital health monitoring platform, HealthPROMISE, leads to better quality of care and improved health outcomes in IBD patients. IBD patients were recruited in gastroenterology clinics and asked to install the HealthPROMISE application onto their smartphones. Patient satisfaction, quality of care, quality of life, patient symptoms, and resource utilization metrics were collected throughout the study and sent directly to their healthcare teams. Patients with abnormal symptom/SIBDQ scores were flagged for their physicians to follow up. After one-year, patient outcome metrics were compared to baseline values. Overall, out of 59 patients enrolled in the study, 32 patients (54%) logged into the application at least once during the study period. The number of IBD-related ER visits/hospitalizations in the year of use compared to the prior year demonstrated a significant decrease from 25% of patients (8/32) to 3% (1/32) (p = 0.03). Patients also reported an increase in their understanding of the nature/causes of their condition after using the application (p = 0.026). No significant changes were observed in the number of quality indicators met (p = 0.67) or in SIBDQ scores (p = 0.48). Given the significant burden of IBD, there is a need to develop effective management strategies. This study demonstrated that digital health monitoring platforms may aid in reducing the number of ER visits and hospitalizations in IBD patients.

scholarly journals An Autoimmune Protocol Diet Improves Patient-Reported Quality of Life in Inflammatory Bowel Disease

2019 ◽  
Vol 1 (3) ◽  
Author(s):  
Anita Chandrasekaran ◽  
Shauna Groven ◽  
James D Lewis ◽  
Susan S Levy ◽  
Caroline Diamant ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Dietary Intervention ◽  
Maintenance Phase ◽  
Fecal Calprotectin ◽  
Dietary Modification ◽  
Patient Reported ◽  
Inflammatory Bowel

Abstract Background Prior studies suggest dietary modification may improve clinical response or remission rates in patients with inflammatory bowel disease (IBD). Our aim was to examine whether an autoimmune protocol diet improves quality of life in patients with active Crohn disease (CD) and ulcerative colitis (UC). Methods We conducted an uncontrolled clinical trial of the autoimmune protocol diet in adult patients with active IBD (Harvey–Bradshaw Index ≥ 5 for CD or partial Mayo score ≥ 3 for UC, and erosions/ulcers on endoscopy and/or elevated fecal calprotectin). The dietary intervention consisted of a 6-week elimination phase, followed by a 5-week maintenance phase. Short Inflammatory Bowel Disease Questionnaire (SIBDQ) was completed at baseline, and weeks 3, 6, 9, and 11. Results The final cohort included 6 UC and 9 CD participants. Mean SIBDQ score improved significantly from baseline (46.5) to weeks 3 (54.0, P = 0.02), 6 (53.3, P = 0.02), 9 (62.0, P = 0.03), and 11 (60.5, P = 0.05). Among participants completing all 5 surveys, mean SIBDQ increased from 46.5 to 61.5 by week 11 (P = 0.03). By week 3, participants experienced significant improvements in bowel movement frequency (36%, P = 0.04), stress (28%, P = 0.01), and ability to perform leisure/sport activities (29%, P = 0.02). Effects were not significantly different between CD and UC participants. Conclusions Dietary modification can improve quality of life as early as week 3 in patients with active IBD. Larger randomized controlled trials are needed to examine dietary interventions in IBD.

scholarly journals Evaluating the Comparative Effectiveness of Two Diets in Pediatric Inflammatory Bowel Disease: A Study Protocol for a Series of N-of-1 Trials

Healthcare ◽  
2019 ◽  
Vol 7 (4) ◽  
pp. 129 ◽  
Author(s):  
Heather Kaplan ◽  
Lisa Opipari-Arrigan ◽  
Christopher Schmid ◽  
Christine Schuler ◽  
Shehzad Saeed ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Comparative Effectiveness ◽  
Research Question ◽  
Population Level ◽  
Fecal Calprotectin ◽  
Mobile App ◽  
Patient Reported ◽  
Inflammatory Bowel ◽  
Restrictive Diet

Inflammatory bowel disease (IBD) affects 3 million children and adults in the US. Treatment involves medications with considerable risk profiles. Dietary modification, such as the specific carbohydrate diet (SCD), may be helpful in treating IBD, but there is insufficient evidence of its effectiveness. N-of-1 trials are ideal for addressing this important research question. The Personalized Research on Diet in Ulcerative Colitis and Crohn’s Disease (PRODUCE) study employs a series of 50 individual N-of-1 trials that compare the SCD to a modified SCD. Treatment periods are assigned in blocks of two, with each patient completing two balanced treatment blocks. Patients are randomized to start with the SCD or modified SCD and alternate between conditions for four eight-week periods. A mobile app guides collecting and viewing data, transitioning diets, and reviewing personal results. Primary outcomes include patient reported outcomes (PROs) of stool frequency, stool consistency, pain interference, and gastrointestinal (GI) symptom severity. We examine changes in inflammation via fecal calprotectin. Participants will receive a personalized answer regarding comparative effectiveness between the SCD and a less restrictive diet option (modified SCD), as well as compared to their baseline diet. We will aggregate the results of completed N-of-1 trials across patients to estimate population level comparative effectiveness of these treatments and the effectiveness of each diet.

scholarly journals A Novel Patient-Reported Outcome-Based Evaluation (PROBE) of Quality of Life in Patients With Inflammatory Bowel Disease

2019 ◽  
Vol 114 (4) ◽  
pp. 640-647 ◽  
Author(s):  
Edward L. Barnes ◽  
Michael D. Kappelman ◽  
Millie D. Long ◽  
Donna M. Evon ◽  
Christopher F. Martin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Patient Reported Outcome ◽  
Patient Reported ◽  
Inflammatory Bowel

scholarly journals A36 IMPACT OF DIGITAL HEALTH MONITORING IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 307-309
Author(s):  
J Zhen ◽  
J Marshall ◽  
G C Nguyen ◽  
A Atreja ◽  
N Narula
Keyword(s):  
Inflammatory Bowel Disease ◽  
Quality Of Care ◽  
Health Monitoring ◽  
Bowel Disease ◽  
Digital Health ◽  
Management Strategies ◽  
Care Quality ◽  
Mobile Health Applications ◽  
Inflammatory Bowel

Abstract Background Inflammatory bowel disease (IBD) affects over 270,000 Canadians and costs the healthcare system $1.28 billion dollars annually. With advancements in technology, a shift from the traditional ‘reactive’ approach to IBD management to a ‘proactive’ approach that integrates self-management strategies using digital health monitoring platforms could greatly benefit patient care. Aims The purpose of this study was to investigate the effect of implementing the IBD health monitoring platform, HealthPROMISE, in clinical practice and to evaluate whether its use leads to better quality of care, improved health outcomes, and reduce resource consumption in patients with IBD. Methods IBD patients were recruited in gastroenterology clinics and asked to install the HealthPROMISE application onto their smartphones. Patient satisfaction, quality of care, quality of life, patient symptoms, and resource utilization metrics were collected throughout the study and sent directly to their healthcare teams. Patients with abnormal symptom/short inflammatory bowel disease questionnaire (SIBDQ) scores were flagged for their physicians to follow up with. After one-year, patient outcome metrics were compared to baseline values. Results Overall, out of 59 patients enrolled in the study, 32 patients (54%) logged into the application at least once during the study period. The number of IBD-related ER visits/hospitalizations in the year of use compared to the prior year demonstrated a significant decrease from 25% of patients (8/32) to 3% (1/32) (p=0.03). Patients also reported an increase in their understanding of the nature/causes of their condition after using the application (p=0.026). No significant changes were observed in the number of quality indicators met (p = 0.67) or in SIBDQ scores (p=0.48). Conclusions Given the significant burden of IBD, there is a need to develop effective management strategies. This study demonstrated that digital health monitoring platforms may aid in reducing the number of ER visits and hospitalizations in IBD patients. Future studies evaluating acceptability and costs with a larger sample size would help determine the feasibility and generalizability of widely implementing mobile health applications in the management of IBD. Funding Agencies CCC

scholarly journals HealthPROMISE: Utilization of Patient Reported Outcomes to Measure Quality of Life in Inflammatory Bowel Disease

Iproceedings ◽  
2017 ◽  
Vol 3 (1) ◽  
pp. e28 ◽  
Author(s):  
Ashish Atreja ◽  
Emamuzo Otobo ◽  
Helena Chang ◽  
Laurie Keefer ◽  
Jason Rogers ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Patient Reported Outcomes ◽  
Patient Reported ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document